These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29157884)

  • 21. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.
    Wang XJ; Goh DYT; Dorajoo SR; Chan A
    Support Care Cancer; 2017 Sep; 25(9):2815-2822. PubMed ID: 28401314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors for poor prognosis febrile neutropenia.
    Ahn S; Lee YS
    Curr Opin Oncol; 2012 Jul; 24(4):376-80. PubMed ID: 22476191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Initial management of febrile neutropenia].
    Badertscher L; Damak H; Mercier L; Décosterd D
    Rev Med Suisse; 2016 Aug; 12(526):1321-1325. PubMed ID: 28671776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical analysis of febrile neutropenia in urological anticancer chemotherapy: retrospective single center study.
    Nishiyama N; Takahashi S; Mizuno T; Uehara T; Hashimoto J; Kurimura Y; Masumori N
    Int J Clin Oncol; 2015 Oct; 20(5):1012-7. PubMed ID: 25652906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia.
    Taj M; Nadeem M; Maqsood S; Shah T; Farzana T; Shamsi TS
    Indian J Hematol Blood Transfus; 2017 Sep; 33(3):355-360. PubMed ID: 28824237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.
    Uys A; Rapoport BL; Fickl H; Meyer PW; Anderson R
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):475-83. PubMed ID: 17944761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies.
    Cherif H; Johansson E; Björkholm M; Kalin M
    Haematologica; 2006 Feb; 91(2):215-22. PubMed ID: 16461306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
    Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
    J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of the Multinational Association for Supportive Care in Cancer (MASCC) Risk Index Score as a Criterion for Nonadmission in Febrile Neutropenic Patients with Solid Tumors.
    Bitar RA
    Perm J; 2015; 19(3):37-47. PubMed ID: 26176568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous stem cell transplantation].
    Zikesoá E; Hnátková M; Vacková B; Jedlicková A; Klener P; Trnený M
    Cas Lek Cesk; 2006; 145(5):383-6, 388-9. PubMed ID: 16755776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Usefulness of the MASCC scale in the management of neutropenic fever induced by chemotherapy in patients with solid neoplasm].
    Gayol Mdel C; Font A; Casas I; Estrada O; Domínguez MJ; Pedro-Botet ML
    Med Clin (Barc); 2009 Sep; 133(8):296-9. PubMed ID: 19376542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Assessment of Febrile Neutropenia in the Emergency Department.
    Carmona-Bayonas A; Jiménez-Fonseca P
    Ann Emerg Med; 2017 Nov; 70(5):753-754. PubMed ID: 29056216
    [No Abstract]   [Full Text] [Related]  

  • 37. The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.
    Fujiwara T; Kenmotsu H; Naito T; Kawamura T; Mamesaya N; Kotake M; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Taira T; Murakami H; Omae K; Mori K; Endo M; Takahashi T
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1229-1237. PubMed ID: 28455585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of FDG-PET/CT in patients with febrile neutropenia.
    Vos FJ; Bleeker-Rovers CP; Oyen WJ
    Semin Nucl Med; 2013 Sep; 43(5):340-8. PubMed ID: 23905616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Industry and MASCC-an opportunity not to be missed.
    Epstein JB; Dean DR; Sonis ST
    Support Care Cancer; 2021 Feb; 29(2):559-561. PubMed ID: 33215315
    [No Abstract]   [Full Text] [Related]  

  • 40. Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.
    Wang XJ; Chan A
    Curr Oncol Rep; 2017 Mar; 19(3):20. PubMed ID: 28271398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.